Embattled GlaxoSmithKline hit with another fraud probe

Britain's fraud agency on Tuesday said it had launched a probe into pharmaceutical giant GlaxoSmithKline, which is already subject of a series of investigations into alleged staff corruption.

The Serious Fraud Office (SFO) confirmed it had opened a "formal " into the London-based drugs manufacturer's commercial practices.

"GSK is committed to operating its business to the highest ethical standards and will continue to cooperate fully with the SFO," said a company spokesman, without providing further details.

GSK last month said first-quarter revenues had fallen 10 percent to £5.6 billion (6.9 billion euros, $9.4 billion) after a Chinese impacted sales growth at the company's emerging markets division.

In a further blow, Polish prosecutors in April said they had extended a probe into allegations that GSK bribed doctors into promoting one of its drugs.

The company is also investigating alleged corruption by staff at its pharmaceuticals division in Iraq.

GSK last year admitted that senior employees appeared to have breached Chinese law after Beijing authorities alleged that staff had bribed government officials, pharmaceutical industry groups, hospitals and doctors to promote sales.

add to favorites email to friend print save as pdf

Related Stories

Probe-hit GlaxoSmithKline announces profits slump

Apr 30, 2014

GlaxoSmithKline, the British drugs giant facing a series of probes into alleged staff corruption, announced sliding profits on Wednesday, one week after unveiling a group makeover.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.